FrancophonIA/ELRC3.0 huggingface dataset:
English: Onivyde is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Maltese: Onivyde jiġi bħala konċentrat li jitħallat f'soluzzjoni għall-infużjoni (dripp) ġol-vina.
English: Patients were given Onivyde or 5-fluorouracil plus leucovorin, or the three medicines in combination.
Maltese: Il-pazjenti ngħataw Onivyde jew 5-fluorouracil flimkien ma' leucovorin, jew it-tliet mediċini f'daqqa.
English: As for all medicines, data on the use of Onivyde are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Onivyde hija ssorveljata kontinwament.
English: Onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas.
Maltese: Onivyde huwa mediċina kontra l-kanċer li tintuża biex tikkura forma ta' kanċer tal-frixa msejħa adenokarċinoma metastatika tal-frixa. ‘Metastatika' tfisser li l-kanċer infirex lejn partijiet oħra talġisem.
English: Onivyde was investigated in one main study involving 417 patients with metastatic adenocarcinoma of the pancreas whose cancer got worse despite cancer treatment that contained gemcitabine.
Maltese: Onivyde ġie investigat fi studju wieħed ewlieni li kien jinvolvi 417-il pazjent b'adenokarċinoma metastatika tal-frixa li l-kanċer tagħhom iggrava minkejja l-kura ta' kontra l-kanċer li kien fiha gemcitabine.
English: Onivyde must not be given to patients who had a severe hypersensitivity (allergic) reaction to irinotecan in the past and to breastfeeding women.
Maltese: Onivyde m'għandux jingħata lil pazjenti li kellhom reazzjoni ta' ipersensittività (allerġika) severa għallirinotekan fil-passat u lil nisa li qed ireddgħu.
English: It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA, which is needed to make new cells.
Maltese: Meta timblokka l-enzima, dan jipprevjeni liċ-ċelloli tal-kanċer milli jimmultiplikaw u eventwalment imutu.
English: Imatinib Accord is available as tablets (100 and 400 mg).
Maltese: Imatinib Accord jiġi f'pilloli (100 u 400 mg).
English: The full EPAR for Imatinib Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The active substance in Imatinib Accord, imatinib, is a protein-tyrosine kinase inhibitor.
Maltese: Is-sustanza attiva f'Imatinib Accord, l-imatinib, hija inibitur tal-proteina tirosina kinażi.
English: This is a summary of the European public assessment report (EPAR) for Imatinib Accord.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Imatinib Accord.
English: Imatinib Accord is used when the patients are ‘Philadelphia chromosome positive' (Ph+).
Maltese: Imatinib Accord jintuża meta l-pazjenti jkunu ‘pożittivi għall-kromożoma ta' Filadelfja' (Ph+).
English: Imatinib Accord contains the active substance imatinib.
Maltese: Imatinib Accord fih is-sustanza attiva imatinib.
English: Imatinib Accord is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα;
Maltese: Imatinib Accord jintuża għall-kura tal-adulti bl-HES jew bis-CEL li għandhom- arranġament mill-ġdid speċifiku ta' żewġ ġeni msejħa FIP1L1 u PDGFRα;
English: Imatinib Accord is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Maltese: Imatinib Accord jintuża fil-kura ta' adulti bil-MD/MPD li kellhom arranġamenti mill-ġdid tal-ġene għar-riċettur tal-fattur tat-tkabbir derivat mill-pjastrini (PDGFR);
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Glivec, and do not need to be repeated for Imatinib Accord.
Maltese: Diġà saru studji dwar il-benefiċċji u r-riskji tas-sustanza attiva fl-użu approvat mal-mediċina ta' referenza, Glivec, u ma għandhomx għalfejn jiġu ripetuti għal Imatinib Accord.
English: Because Imatinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Imatinib Accord huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Imatinib Accord is used in combination with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL.
Maltese: Imatinib Accord jintuża flimkien ma' mediċini oħra kontra l-kanċer f'adulti u tfal li ġew dijanjostikati riċentement bil-Ph+ ALL.
English: The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine, Glivec.
Maltese: Il-kumpanija għamlet studji li wrew li hija 'bijoekwivalenti' għall-mediċina ta' referenza, Glivec.
English: Why is Imatinib Accord approved?
Maltese: Għaliex ġie approvat Imatinib Accord?
English: Imatinib Accord is a cancer medicine used to treat the following diseases:
Maltese: Imatinib Accord huwa mediċina ta' kontra l-kanċer użata għall-kura tal-mard li ġej:
English: For more information on generic medicines, see the question-and-answer document here.
Maltese: Għal aktar informazzjoni dwar il-mediċini ġeneriċi, ara ddokument ta' mistoqsijiet u tweġibiet hawnhekk.
English: Imatinib Accord is used in adults and children who have been newly diagnosed with Ph+ CML and who are not eligible for bone marrow transplantation.
Maltese: Imatinib Accord jintuża fl-adulti u t-tfal li ġew dijanjostikati reċentement bil-Ph+ CML u li mhumiex eliġibbli għal trapjant tal-mudullun.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Imatinib Accord has been shown to have comparable quality and to be bioequivalent to Glivec.
Maltese: L-Aġenzija Ewropea għall-Mediċini ikkonkludiet li, f'konformità mar-rekwiżiti tal-UE, Imatinib Accord wera li għandu kwalità komparabbli u li huwa bijoekwivalenti ma' Glivec.
English: Imatinib Accord is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Maltese: Imatinib Accord jingħata mill-ħalq ma' ikla u tazza ilma kbira biex jitnaqqas ir-riskju ta' irritazzjoni talistonku u tal-intestini.
English: This means that Imatinib Accord contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Glivec.
Maltese: Dan ifisser li Imatinib Accord fih l-istess sustanza attiva u jaħdem bl-istess mod bħal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) imsejħa Glivec.
English: It is also used in adults and children in the ‘chronic phase' of the disease if it is not responding to interferon alfa (another cancer medicine), and in more advanced phases of the disease (‘accelerated phase' and ‘blast crisis');
Maltese: Jintuża wkoll f'adulti u tfal li jinsabu fil-‘fażi kronika' tal-marda jekk ma tkunx qed tirrispondi għall-interferon alfa (mediċina oħra kontra l-kanċer), u f'fażijiet oħra aktar avvanzati tal-marda (‘fażi aċċellerata' u ‘terminali');
English: The Agency recommended that Imatinib Accord be approved for use in the EU.
Maltese: L-Aġenzija rrakkomandat li Imatinib Accord ikun approvat għall-użu fl-UE.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Imatinib Accord on 1 July 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Imatinib Accord fl-1 ta' Lulju 2013.
English: What are the benefits and risks of Imatinib Accord?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Imatinib Accord?
English: • chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
Maltese: • lewkimja mjelojde kronika (CML), kanċer taċ-ċelloli l-bojod tad-demm fejn il-granuloċiti (tip ta' ċellola bajda tad-demm) jibdew jikbru mingħajr kontroll.
English: Abstract Book of the 2014 Annual Meeting of the American Association of Clinical Endocrinologists (AACE), p. 238, abstract #1353.
Maltese: Annual Meeting of the American Association of Clinical Endocrinologists (AACE), p. 238, abstract #1353.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom21 November 2014 EMA/706140/2014
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom21 ta' Novembru 2014
English: Available at: https://www.aace.com/files/late-breaking-abstracts2014.pdf
Maltese: Available at: https://www.aace.com/files/late-breakingabstracts-2014.pdf 7.
English: BMC Med 2013; 11: 108.
Maltese: Med 2013; 11: 108.
English: The review of testosterone was initiated on 27 March 2014 at the request of Estonia, under Article 31 of Directive 2001/83/EC.
Maltese: Ir-rieżami ta' testosterone nbdiet fis-27 ta' Marzu 2014 fuq talba tal-Estonja skont l-Artikolu 31 tadDirettiva 2001/83/KE.
English: Possible signs and symptoms include incomplete sexual development, decreased sexual function, infertility, fatigue, depressed mood, mild anaemia, reduced muscle bulk and strength and increased body fat.
Maltese: Sinjali u sintomi possibbli jinkludu żvilupp sesswali mhux komplet, tnaqqis fil-funzjoni sesswali, infertilità, għeja, burdata depressa, anemija ħafifa, massa u saħħa tal-muskoli mnaqqsa u żieda fix-xaħam tal-ġisem.
English: Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.
Maltese: Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.
English: Information to patients
Maltese: Informazzjoni għall-pazjenti
English: Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone boosting medications: a systematic review and metaanalysis.
Maltese: Cardiovascular risk associated with testosterone boosting medications: a systematic review and metaanalysis.
English: • There is limited experience on the safety and efficacy of the use of these medicines in patients over 65 years of age.
Maltese: • Hemm esperjenza limitata fuq is-sigurtà u l-effikaċja tal-użu ta' dawn il-mediċini f'pazjenti ta' aktar minn 65 sena.
English: Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels.
Maltese: Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98: 1891
English: Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.
Maltese: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.
English: • However, other findings4-7 do not provide evidence of an association between testosterone and cardiovascular events, and data from a multinational observational registry study (RHYME) looking at prostate health outcomes in men treated with testosterone for over 2 years also indicate cardiovascular events within the anticipated range.
Maltese: • Madankollu, sejbiet oħrajn4-7 ma jipprovdux evidenza ta' assoċjazzjoni bejn testosterone u avvenimenti kardjovaskulari, u data minn studju ta' osservazzjoni tar-reġistru multinazzjonali (RHYME) li ħares lejn ir-riżultati tas-saħħa tal-prostata f'irġiel ikkurati b'testosterone għal aktar minn sentejn indikat ukoll avvenimenti kardjovaskulari fil-firxa mistennija.
English: • Testosterone replacement therapy should only be given when deficiency of the hormone has been confirmed by clinical features and biochemical tests.
Maltese: • Terapija ta' sostituzzjoni tat-testosterone għandha tingħata biss meta nuqqas tal-ormon jiġi kkonfermat b'elementi kliniċi u b'testijiet bijokimiċi.
English: • There is not much information on the use of testosterone medicines in men over 65 years of age.
Maltese: • M'hemmx wisq informazzjoni dwar l-użu ta' mediċini li fihom testosterone f'irġiel ta' aktar minn 65 sena.
English: The CMDh, a body representing EU Member States, is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU.
Maltese: Is-CMDh, korp li jirrappreżenta lill-Istati Membri tal-UE, huwa responsabbli li jiżgura standards ta' sigurtà armonizzati għal mediċini awtorizzati permezz ta' proċeduri nazzjonali madwar l-UE.
English: The PRAC recommendations were sent to the CMDh, which adopted a final position.
Maltese: Ir-rakkomandazzjonijiet tal-PRAC intbagħtu lisCMDh, li adotta pożizzjoni finali.
English: • As a precaution, the product information for these medicines will be updated with the latest information on the risks together with some additional warnings for safe use, and the safety of the medicines will continue to be closely monitored.
Maltese: • Bħala prekawzjoni, l-informazzjoni dwar il-prodott għal dawn il-mediċini sejra tiġi aġġornata blaħħar informazzjoni dwar ir-riskji flimkien ma xi twissijiet addizzjonali għal użu sikur, u s-sigurtà tal-mediċini sejra tibqa' tiġi ssorveljata mill-qrib.
English: • Testosterone is a hormone responsible for normal sexual development and function in men.
Maltese: • Testosterone huwa ormon responsabbli mill-żvilupp u l-funzjoni sesswali normali fl-irġiel.
English: Testosterone is a hormone, known as an androgen, responsible for the development and maintenance of reproductive function and sexual characteristics in men.
Maltese: Testosterone huwa ormon, magħruf bħala androġenu, responsabbli mill-iżvilupp u l-manteniment talfunzjoni riproduttiva u l-karatteristiċi sesswali fl-irġiel.
English: The changes to the product information for testosterone medicines are based on a PRAC review of data available from clinical trials, observational studies, meta-analyses, post-marketing data and further published data on the cardiovascular risks associated with testosterone therapy.
Maltese: Il-bidliet fl-informazzjoni dwar il-prodott għal mediċini li fihom testosterone huma bbażati fuq reviżjoni tal-PRAC tad-data disponibbli minn provi kliniċi, studji ta' osservazzjoni, meta-analiżijiet, data ta' wara t-tqegħid fis-suq u aktar data ppubblikata fuq ir-riskji kardjovaskulari assoċjati ma' terapija b'testosterone.
English: They are available as various formulations such as oral capsules, implants to be injected under the skin and as patches, gels or solutions to be applied to the skin.
Maltese: Huma disponibbli f'diversi formulazzjonijiet bħal kapsuli orali, impjanti li jiġu injettati taħt il-ġilda u bħala impjastri, ġell jew soluzzjonijiet li jiġu applikati fuq il-ġilda.
English: However, the product information is to be updated in line with the most current available evidence on safety, and with warnings that the lack of testosterone should be confirmed by signs and symptoms and laboratory tests before treating men with these medicines.
Maltese: Madankollu, l-informazzjoni dwar il-prodott għandha tiġi aġġornata f'konformità mal-evidenza disponibbli dwar is-sigurtà l-aktar attwali, u bi twissijiet li n-nuqqas ta' testosterone għandu jiġi kkonfermat b'sinjali u sintomi u testijiet fil-laboratorji qabel ma jiġu kkurati irġiel b'dawn il-mediċini.
English: Baillargeon J, Urban RJ, Kuo Y-F, et al. Risk of myocardial infarction in older men receiving testosterone therapy.
Maltese: B'mod partikolari, tqajjem tħassib fir-rigward ta' żieda fir-riskju potenzjali ta' avvenimenti kardjovaskulari, b'mod partikolari infart mijokardjali, f'irġiel ikkurati b'testosterone u li għandhom mard tal-qalb pre-eżistenti.
English: • Some recent studies have shown an increased risk of cardiovascular events in men treated with testosterone.
Maltese: Risk of myocardial infarction in older men receiving testosterone therapy.
English: The PRAC considered these studies along with available data from other studies and analyses, and information on safety collected since marketing, and found that the evidence regarding the risk of heart problems was inconsistent: some studies suggested increased risk, while others did not, and some of the studies had problems with the design that limited the conclusions that could be drawn from them.
Maltese: Il-PRAC irrakkomanda l-aġġornar tal-informazzjoni dwar il-prodott f'konformità mal-aħħar evidenza u li jiġu pprovduti twissijiet dwar dawk li jistgħu jkunu f'riskju miżjud ta' problemi tal-qalb.
English: The CMDh1, a regulatory body representing EU Member States, has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with testosterone medicines in men who lack the hormone (a condition known as hypogonadism).
Maltese: Is-CMDh1, korp regolatorju li jirrappreżenta l-Istati Membri tal-UE, qabel b'kunsens li ma hemm ebda evidenza konsistenti ta' riskju miżjud ta' problemi tal-qalb b'mediċini li fihom testosterone f'irġiel li għandhom nuqqas tal-ormon (kundizzjoni magħrufa bħala ipogonadiżmu).
English: The full EPAR for Ecansya can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Ecansya is a ‘generic' and a ‘hybrid' medicine.
Maltese: Ecansya huwa mediċina ‘ġenerika' u ‘ibrida'.
English: Ecansya capecitabine
Maltese: Ecansya kapesitabina
English: It is available as tablets (150, 300 and 500 mg).
Maltese: Jiġi f'għamla ta' pilloli (150, 300 u 500 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Capecitabine Krka on 20 April 2012.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Capecitabine Krka fl-20 ta' April 2012.
English: This is a summary of the European public assessment report (EPAR) for Ecansya.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Ecansya.
English: This means that it is similar to a ‘reference medicine', but it contains capecitabine at a new strength in addition to existing strengths: while the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Ecansya is also available as 300 mg tablets.
Maltese: Dan ifisser li huwa simili għal ‘mediċina ta' referenza', iżda fih il-kapesitabina f'qawwa ġdida minbarra l-qawwiet eżistenti: filwaqt li l-mediċina ta' referenza, Xeloda, tiġi f'pilloli ta' 150 u 500 mg, Ecansya jiġi wkoll f'pilloli ta' 300 mg.
English: The CHMP concluded that, in accordance with EU requirements, Ecansya has been shown to have comparable quality and to be bioequivalent to Xeloda.
Maltese: Is-CHMP kkonkluda li, f'konformità mar-rekwiżiti tal-UE, intwera li Ecansya għandu kwalità kumparabbli u huwa bijoekwivalenti għal Xeloda.
English: Ecansya is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient's height and weight).
Maltese: Ecansya jittieħed darbtejn kuljum b'dożi ta' bejn 625 u 1,250 mg għal kull metru kwadru tas-superfiċje tal-ġisem (ikkalkulat permezz tat-tul u l-piż tal-pazjent).
English: Why has Ecansya been approved?
Maltese: Għaliex ġie approvat Ecansya?
English: Ecansya is an anticancer medicine.
Maltese: Ecansya huwa mediċina kontra l-kanċer.
English: The company provided data from the published literature on capecitabine.
Maltese: Il-kumpanija pprovdiet dejta minn dokumentazzjoni ppubblikata dwar il-kapesitabina.
English: The company carried out a ‘bioequivalence' study to show that 500 mg Ecansya produces the same levels of capecitabine in the blood as 500 mg of the reference medicine.
Maltese: Il-kumpanija għamlet studju ‘bijoekwivalenti' biex turi li 500 mg ta' Ecansya jipproduċu l-istess livelli ta' kapesitabina fid-demm bħat-teħid bħal 500 mg tal-mediċina ta' referenza.
English: Ecansya is a medicine that contains the active substance capecitabine.
Maltese: Ecansya huwa mediċina li fiha s-sustanza attiva kapeċitabina.
English: Ecansya is used with docetaxel (another anticancer medicine) after treatment with anthracyclines (another type of anticancer medicine) has failed.
Maltese: Ecansya jintuża mad-doketaxel (mediċina oħra kontra l-kanċer) wara li l-għoti ta' trattament bl-antraċiklini (tip ieħor ta' mediċini kontra l-kanċer) ikun falla.
English: It is taken as tablets, while 5-FU normally needs to be injected.
Maltese: Tittieħed f'pilloli, waqt li 5-FU normalment tkun trid tiġi injettata.
English: It is used to treat:
Maltese: Jintuża fit-trattament ta':
English: The active substance in Ecansya, capecitabine, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anti-metabolites'.
Maltese: Is-sustanza attiva f'Ecansya, il-kapeċitabina, hija mediċina ċitotossika (mediċina li toqtol liċ-ċelloli li jkunu qed jimmultiplikaw, bħaċ-ċelloli tal-kanċer) li jappartienu lill-grupp tal-‘antimetaboliti'.
English: Capecitabine is a ‘prodrug' that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Maltese: Ilkapesitabina hija ‘promediċina' li tiġi metabolizzata fil-ġisem bħala f'5-fluorouracil (5-FU), iżda fiċċelloli tat-tumuri din tiġi kkonvertita iktar f'ċelloli tal-kanċer milli f'tessuti f'saħħithom.
English: Because Ecansya is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Ecansya huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Ecansya is used with or without other anticancer medicines in patients who have had surgery for ‘stage III' or ‘Dukes' stage C' colon cancer;
Maltese: Ecansya jintuża waħdu jew ma' mediċini oħra kontra lkanċer fuq pazjenti li kien sarilhom intervent kirurġiku għal kanċer tal-kolon fil-‘fażi III' jew fil-‘fażi Ċ ta' Dukes;
English: What is Ecansya?
Maltese: X'inhu Ecansya?
English: Ecansya tablets should be swallowed with water within the 30 minutes after a meal.
Maltese: Il-pilloli ta' Ecansya għandhom jinbelgħu mal-ilma sa 30 minuta wara l-ikel.
English: The name of the medicine was changed to Ecansya on 16 November 2012.
Maltese: L-isem tal-mediċina nbidel u sar Ecansya fis-16 ta' Novembru
English: Ecansya is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin;
Maltese: Ecansya jintuża flimkien ma' medicini oħra kontra lkanċer, inklużi mediċini kontra l-kanċer li jkun fihom il-platinu bħaċ-ċisplatina;
English: How has Ecansya been studied?
Maltese: Kif ġie studjat Ecansya?
English: • colon (large bowel) cancer.
Maltese: • kanċer tal-kolon (tal-musrana l-għamja).
English: What are the benefits and risks of Ecansya?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Ecansya?
English: Treatment is continued for six months after colon surgery.
Maltese: It-trattament jitkompla tul sitt xhur wara l-intervent kirurġiku fil-musrana l-għamja.
English: For more information on generic and hybrid medicines, see the question-and-answer document here.
Maltese: Għal aktar tagħrif dwar ilmediċini ġeneriċi u ibridi, ara d-dokument mistoqsijiet-u-tweġibiet hawnhekk.
English: • locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Maltese: • kanċer tas-sider lokalment avvanzat jew metastatiku (kanċer tas-sider li beda jinfirex ma' partijiet oħra tal-ġisem).
English: The doctor will calculate the number of 150, 300 and 500 mg tablets the patient needs to take.
Maltese: It-tabib għandu jikkalkula l-għadd ta' pilloli ta' 150, 300 u 500 mg li l-pazjent ikollu bżonn jieħu.
English: The full EPAR for Docetaxel Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It contains the active substance docetaxel.
Maltese: Fih issustanza attiva docetaxel.